AAD2026:Late-BreakingNemolizumabDataDemonstrateClinicallyMeaningfulBenefitsforChildrenAged2to11WithModerate-to-SevereAtopicDermatitis
===2026/3/30 11:39:27===
dults and adolescent patients with moderate-to-severe atopic dermatitis and adults with prurigo nodularis, including in the U.S. and European Union.2,3
For more information about the impact of atopic dermatitis on children and families, watchthis video. Media can find more information and resources on atopic dermatitis inthis toolkit.
About Galderma
Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that
=*=*=*=*=*=
当前为第6/10页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页